Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BETH ISRAEL DEACONESS MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1896-01-01

Employees: -

Market Cap: -

Website: https://www.bidmc.org/

Clinical Trials

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Phase 2

Completed

Conditions: AML
ALL
CLL
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Multiple Myeloma
Aplastic Anemia
Myeloproliferative Disorder

First Posted Date: 2007-09-24

Last Posted Date: 2016-07-18

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 25

Registration Number: NCT00533923

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

Not Applicable

Completed

Conditions: Migraine

Interventions: Device: DC Stimulator (Transcranial Direct Current Stimulator)

First Posted Date: 2007-08-27

Last Posted Date: 2017-03-21

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 13

Registration Number: NCT00521196

Locations: 🇺🇸
Beth Israel Deaconess Medical Center: Berenson-Allen Center for Noninvasive Brain Stimulation, Boston, Massachusetts, United States

Effects of Dietary Manipulation on Metabolism in Healthy Adults

Not Applicable

Completed

Conditions: Ketogenic Diet
Metabolic Regulation
Fasting

Interventions: Behavioral: Dietary Manipulation - 12 day ketogenic diet
Behavioral: Dietary manipulation ketogenic diet
Behavioral: 16 Hour Fast

First Posted Date: 2007-05-21

Last Posted Date: 2023-08-14

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 20

Registration Number: NCT00476125

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

Phase 1

Completed

Conditions: Renal Cancer

Interventions: Biological: Dendritic Cell Tumor Fusion Vaccine
Drug: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)

First Posted Date: 2007-04-11

Last Posted Date: 2024-04-03

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 38

Registration Number: NCT00458536

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

First Posted Date: 2007-04-11

Last Posted Date: 2010-01-12

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 18

Registration Number: NCT00459069

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: Dendritic Cell Tumor Fusion

First Posted Date: 2007-04-11

Last Posted Date: 2023-06-22

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 45

Registration Number: NCT00458653

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States

and more 1 locations

Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Everolimus
Drug: Trastuzumab

First Posted Date: 2007-04-10

Last Posted Date: 2016-10-20

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 11

Registration Number: NCT00458237

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

Phase 4

Completed

Conditions: Obesity
Impaired Glucose Tolerance

Interventions: Drug: exenatide
Drug: Placebo

First Posted Date: 2007-04-05

Last Posted Date: 2017-09-11

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 41

Registration Number: NCT00456885

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Radiosurgery for Glioblastoma Multiforme

Phase 1

Terminated

Conditions: Glioblastoma Multiforme

Interventions: Procedure: CyberKnife

First Posted Date: 2007-04-05

Last Posted Date: 2017-03-06

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 4

Registration Number: NCT00456612

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Restricted Fluid Regimen in Open Abdominal Bowel Surgery

Not Applicable

Withdrawn

Conditions: Bowel Surgery

Interventions: Other: intraoperative fluid management
Other: fluid restriction

First Posted Date: 2007-04-05

Last Posted Date: 2017-03-06

Lead Sponsor: Beth Israel Deaconess Medical Center

Registration Number: NCT00456703

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy